Trial intelligence / Profile preview

BBB-PET

2024-518865-85-00Phase 2Authorised

Sponsor: University Medical Center Groningen
Start: Dec 2024
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
Countries: 1

Overview

Phase 2, open-label trial of 18F-MC225 (3 cohorts), sponsored by University Medical Center Groningen. Primary endpoint: Regional [18F]MC225 PET tracer uptake and influx values. Planned start Dec 2024; status: authorised.

Drugs

18F-MC225

Beyond the preview

Go deeper on 2024-518865-85-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-518865-85-00.